Juvisé Pharmaceuticals acquires rights to MS therapy Ponvory outside North America
04/02/24, 5:32 PM
Location
paris
new brunswickIndustry
therapeutics
health care
pharmaceutical
medical
biotechnology
Juvisé Pharmaceuticals, a French pharmaceutical company, has acquired the global rights to develop and market the approved multiple sclerosis (MS) therapy Ponvory (ponesimod) outside the U.S. and Canada. The rights were acquired from Actelion Pharmaceuticals, the therapy’s original developer and now part of Johnson & Johnson Innovative Medicine. This strategic acquisition aligns with Juvisé Pharmaceuticals' commitment to expanding its portfolio with strong development potential and providing essential medications to patients and specialist doctors.
Company Info
Location
Paris, Ile De France, France
Company info
Juvisé Pharmaceuticals, based in Paris, France, is a leading pharmaceutical company with a focus on enhancing patient care by providing access to treatments with high medical value. With a rich history of essential medicines in oncology, cardiology, gastroenterology, neuropsychiatry, and rheumatology, Juvisé Pharmaceuticals prioritizes making treatments accessible to millions of patients worldwide. The company is known for its presence in 80 countries across five continents.